blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP2790021

EP2790021 - Bimarkers for schizophrenia or other psychotic disorders. [Right-click to bookmark this link]
Former [2014/42]Bimarkers for schizophrenia or other psychotic disorders.
[2014/48]
StatusThe application is deemed to be withdrawn
Status updated on  29.04.2016
Database last updated on 25.09.2024
Most recent event   Tooltip29.04.2016Application deemed to be withdrawnpublished on 01.06.2016  [2016/22]
Applicant(s)For all designated states
Cambridge Enterprise Limited
The Old Schools Trinity Lane Cambridge
Cambridgeshire CB2 1TN / GB
[2014/42]
Inventor(s)01 / Bahn, Sabine
Department of Chemical Engineering & Biotechnology
Institute of Biotechnology
University of Cambridge
Tennis Court Road
Cambridge, Cambridgeshire CB2 1QT / GB
02 / Levin, Yishai
Hashahaf Street 24
PO Box 4782
38523 Hadera / IL
 [2014/42]
Representative(s)Gibson, Mark
Sagittarius IP
Marlow International
Parkway
Marlow SL7 1YL / GB
[N/P]
Former [2014/42]Gibson, Mark
Sagittarius IP
Three Globeside
Fieldhouse Lane
Marlow, Buckinghamshire SL7 1HZ / GB
Application number, filing date14170410.609.09.2010
[2014/42]
Priority number, dateGB2009001573609.09.2009         Original published format: GB 0915736
[2014/42]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP2790021
Date:15.10.2014
Language:EN
[2014/42]
Search report(s)(Supplementary) European search report - dispatched on:EP17.09.2014
ClassificationIPC:G01N33/68
[2014/42]
CPC:
G01N33/6893 (EP,US); A61P25/18 (EP); G01N2800/302 (EP,US);
G01N2800/60 (EP,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   SM,   TR [2015/18]
Former [2014/42]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  SE,  SI,  SK,  SM,  TR 
TitleGerman:Bimarker für schizophrenie oder andere psychotische störungen[2015/32]
English:Bimarkers for schizophrenia or other psychotic disorders.[2015/32]
French:Biomarqueurs pour la schizophrénie ou d'autres troubles psychotiques[2014/42]
Former [2014/42]Bimarker für schizophrenie oder andere psychotische störungen
Former [2014/42]Bimarkers for schizophrenia or other psychotic disorders.
Examination procedure19.03.2015Amendment by applicant (claims and/or description)
19.03.2015Examination requested  [2015/18]
17.07.2015Communication of intention to grant the patent
28.11.2015Application deemed to be withdrawn, date of legal effect  [2016/22]
13.01.2016Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time  [2016/22]
Parent application(s)   TooltipEP10755224.2  / EP2475997
Fees paidRenewal fee
17.10.2014Renewal fee patent year 03
17.10.2014Renewal fee patent year 04
07.10.2014Renewal fee patent year 05
Penalty fee
Additional fee for renewal fee
28.05.201403   M06   Fee paid on   17.10.2014
28.05.201404   M06   Fee paid on   17.10.2014
30.09.201405   M06   Fee paid on   07.10.2014
30.09.201506   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[A]US2006099593  (NAWA HIROYUKI [JP], et al) [A] 1-15 * the whole document * * In particular: paragraphs 2, 21-36; tables 1-3; paragraphs 114-202, examples section; Claims 1-20. *;
 [A]WO2008090319  (PSYNOVA NEUROTECH LTD [GB], et al) [A] 1-15 * the whole document * * In particular: p. 1, l. 5 - p. 2, l. 14; Table 1-2; claims 1-54. *;
 [A]  - YANG Y ET AL, "Altered levels of acute phase proteins in the plasma of patients with schizophrenia", ANALYTICAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, (20060601), vol. 78, doi:10.1021/AC051916X, ISSN 0003-2700, pages 3571 - 3576, XP002413130 [A] 1-15 * the whole document * * In particular: Title; Abstract; Tables 1-2. *

DOI:   http://dx.doi.org/10.1021/ac051916x
 [A]  - JIANG L ET AL, "Proteomic analysis of the cerebrospinal fluid of patients with schizophrenia", AMINO ACIDS, SPRINGER VERLAG, AU, (20030317), vol. 25, ISSN 0939-4451, pages 49 - 57, XP002413128 [A] 1-15 * the whole document * * In particular: Title; abstract; Table 1. *
 [A]  - H. ISHIGURO ET AL, "Supportive Evidence for Reduced Expression of GNB1L in Schizophrenia", SCHIZOPHRENIA BULLETIN, (20081114), vol. 36, no. 4, doi:10.1093/schbul/sbn160, ISSN 0586-7614, pages 756 - 765, XP055137295 [A] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1093/schbul/sbn160
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.